Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Journal of Labelled Compounds & Radiopharmaceuticals
|
December 18, 2019
Manual vs automated <sup>68</sup> Ga-radiolabelling-A comparison of optimized processes
Michael Meisenheimer, Stefan Kürpig, Markus Essler, et al.
EJNMMI Radiopharmacy and Chemistry
|
October 30, 2019
Ethanol effects on <sup>68</sup>Ga-radiolabelling efficacy and radiolysis in automated synthesis utilizing NaCl post-processing
Michael Meisenheimer, Stefan Kürpig, Markus Essler, et al.
Molecules (Basel, Switzerland)
|
July 8, 2020
DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine
Michael Meisenheimer, Stefan Kürpig, Markus Essler, et al.
Diagnostics (Basel, Switzerland)
|
September 28, 2021
Radiolabeling Strategies of Nanobodies for Imaging Applications
Jim Küppers, Stefan Kürpig, Ralph A Bundschuh, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 25, 2017
The impact of repeated cycles of radioligand therapy using [<sup>177</sup>Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Anna Yordanova, Anja Becker, Elisabeth Eppard, et al.
Oncotarget
|
February 13, 2016
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig, et al.
Oncotarget
|
September 15, 2017
Radioligand therapy of metastatic prostate cancer using <sup>177</sup>Lu-PSMA-617 after radiation exposure to <sup>223</sup>Ra-dichloride
Hojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 24, 2016
<sup>68</sup>Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with <sup>223</sup>Ra: Proof of Concept
Hojjat Ahmadzadehfar, Kambiz Azgomi, Stefan Hauser, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 27, 2018
Outcome and safety of rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Anna Yordanova, Paula Linden, Stefan Hauser, et al.
Annals of Nuclear Medicine
|
March 17, 2019
Preliminary results of biodistribution and dosimetric analysis of [<sup>68</sup>Ga]Ga-DOTA<sup>ZOL</sup>: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases
Ambreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Journal of Labelled Compounds & Radiopharmaceuticals
|
December 18, 2019
Manual vs automated <sup>68</sup> Ga-radiolabelling-A comparison of optimized processes
Michael Meisenheimer, Stefan Kürpig, Markus Essler, et al.
EJNMMI Radiopharmacy and Chemistry
|
October 30, 2019
Ethanol effects on <sup>68</sup>Ga-radiolabelling efficacy and radiolysis in automated synthesis utilizing NaCl post-processing
Michael Meisenheimer, Stefan Kürpig, Markus Essler, et al.
Molecules (Basel, Switzerland)
|
July 8, 2020
DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine
Michael Meisenheimer, Stefan Kürpig, Markus Essler, et al.
Diagnostics (Basel, Switzerland)
|
September 28, 2021
Radiolabeling Strategies of Nanobodies for Imaging Applications
Jim Küppers, Stefan Kürpig, Ralph A Bundschuh, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 25, 2017
The impact of repeated cycles of radioligand therapy using [<sup>177</sup>Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Anna Yordanova, Anja Becker, Elisabeth Eppard, et al.
Oncotarget
|
February 13, 2016
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig, et al.
Oncotarget
|
September 15, 2017
Radioligand therapy of metastatic prostate cancer using <sup>177</sup>Lu-PSMA-617 after radiation exposure to <sup>223</sup>Ra-dichloride
Hojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 24, 2016
<sup>68</sup>Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with <sup>223</sup>Ra: Proof of Concept
Hojjat Ahmadzadehfar, Kambiz Azgomi, Stefan Hauser, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 27, 2018
Outcome and safety of rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Anna Yordanova, Paula Linden, Stefan Hauser, et al.
Annals of Nuclear Medicine
|
March 17, 2019
Preliminary results of biodistribution and dosimetric analysis of [<sup>68</sup>Ga]Ga-DOTA<sup>ZOL</sup>: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases
Ambreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Page
of 2